Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DXR NASDAQ:LYRA NASDAQ:TMDIF NASDAQ:VVOS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDXRDaxor$9.00-3.7%$8.79$6.55▼$10.00$43.53M-0.075,509 shs6,835 shsLYRALyra Therapeutics$7.90-7.6%$10.19$3.81▼$37.50$10.47M0.24193,967 shs59,644 shsTMDIFTitan Medical$0.38+2.8%$0.29$0.03▼$1.00$43.37M1.2674,785 shs3,116 shsVVOSVivos Therapeutics$5.82+1.6%$3.36$1.97▼$7.95$34.28M7.01620,299 shs268,282 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDXRDaxor0.00%-3.12%0.00%+21.46%-2.17%LYRALyra Therapeutics0.00%-8.67%-26.03%+82.66%-48.42%TMDIFTitan Medical+2.79%+5.18%+47.08%+6.39%+927.95%VVOSVivos Therapeutics0.00%-14.66%+134.68%+177.14%+105.65%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDXRDaxorN/AN/AN/AN/AN/AN/AN/AN/ALYRALyra Therapeutics2.5569 of 5 stars3.22.00.00.01.62.51.3TMDIFTitan MedicalN/AN/AN/AN/AN/AN/AN/AN/AVVOSVivos Therapeutics0.8033 of 5 stars1.35.00.00.01.10.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDXRDaxor 3.00Buy$25.00177.78% UpsideLYRALyra Therapeutics 2.33Hold$100.001,165.82% UpsideTMDIFTitan Medical 0.00N/AN/AN/AVVOSVivos Therapeutics 2.50Moderate Buy$4.82-17.24% DownsideCurrent Analyst Ratings BreakdownLatest LYRA, DXR, TMDIF, and VVOS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025VVOSVivos TherapeuticsIndustrial Alliance SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$2.255/20/2025VVOSVivos TherapeuticsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDXRDaxorN/AN/AN/AN/AN/AN/ALYRALyra Therapeutics$1.53M6.87N/AN/A$8.86 per share0.89TMDIFTitan Medical$17.63M2.46$19.02 per share0.02$1.05 per share0.36VVOSVivos Therapeutics$15.03M2.28N/AN/A$1.35 per share4.31Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDXRDaxorN/AN/A0.00∞N/AN/AN/AN/AN/ALYRALyra Therapeutics-$93.43M-$60.50N/AN/AN/A-6,711.39%-295.52%-66.95%8/13/2025 (Estimated)TMDIFTitan Medical$6.95M$0.05N/A∞N/AN/A-82.31%-51.47%N/AVVOSVivos Therapeutics-$11.14M-$1.73N/AN/AN/A-76.82%-170.43%-77.82%8/13/2025 (Estimated)Latest LYRA, DXR, TMDIF, and VVOS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025LYRALyra Therapeutics-$5.79N/AN/AN/A$0.18 millionN/A8/13/2025Q2 2025VVOSVivos Therapeutics-$0.39N/AN/AN/A$3.37 millionN/A5/15/2025Q1 2025VVOSVivos Therapeutics-$0.44-$0.45-$0.01-$0.45$3.63 million$3.70 million5/6/2025Q1 2025LYRALyra Therapeutics-$7.50-$6.00+$1.50-$0.13$0.16 million$0.18 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDXRDaxorN/AN/AN/AN/AN/ALYRALyra TherapeuticsN/AN/AN/AN/AN/ATMDIFTitan MedicalN/AN/AN/AN/AN/AVVOSVivos TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDXRDaxorN/AN/AN/ALYRALyra TherapeuticsN/A2.962.96TMDIFTitan MedicalN/A3.733.73VVOSVivos TherapeuticsN/A0.770.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDXRDaxor1.34%LYRALyra Therapeutics95.62%TMDIFTitan Medical0.03%VVOSVivos Therapeutics26.35%Insider OwnershipCompanyInsider OwnershipDXRDaxor59.50%LYRALyra Therapeutics3.25%TMDIFTitan Medical0.02%VVOSVivos Therapeutics3.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDXRDaxor374.84 million1.96 millionNot OptionableLYRALyra Therapeutics501.33 million1.28 millionOptionableTMDIFTitan Medical50114.04 million4.56 millionNot OptionableVVOSVivos Therapeutics1605.89 million5.71 millionOptionableLYRA, DXR, TMDIF, and VVOS HeadlinesRecent News About These CompaniesVivos Therapeutics Receives Medicare Approval for VidaSleep™ Oral Appliance - MorningstarJuly 2, 2025 | morningstar.comMVivos Therapeutics Inc. (VVOS) Stock Price Today - WSJJuly 2, 2025 | wsj.comVivos Therapeutics Receives Medicare Approval for VidaSleep™ Oral ApplianceJuly 1, 2025 | taiwannews.com.twTVivos Therapeutics stock soars after Medicare approves VidaSleep oral applianceJuly 1, 2025 | in.investing.comVivos Therapeutics Shares Skyrocket After Medicare Greenlights VidaSleep Oral DeviceJuly 1, 2025 | msn.comVivos Therapeutics Secures CMS Approval for VidaSleep™ Oral Appliance, Expanding Access to Sleep Apnea TreatmentJuly 1, 2025 | quiverquant.comQNew Clinical Trial Data Published Showing Positive Results from Use of Vivos Technology to Treat Obstructive Sleep Apnea in ChildrenJune 26, 2025 | finance.yahoo.comNew Clinical Trial Data Published Showing Positive Results from Use of Vivos Technology to Treat Obstructive Sleep Apnea in ChildrenJune 26, 2025 | globenewswire.comVivos Therapeutics, Inc: Vivos Therapeutics Completes Acquisition of The Sleep Center of NevadaJune 11, 2025 | finanznachrichten.deVivos Therapeutics Completes Acquisition of The Sleep Center of NevadaJune 11, 2025 | finance.yahoo.comVivos Therapeutics Completes Acquisition of The Sleep Center of Nevada, Expanding OSA Diagnostic and Treatment CapabilitiesJune 11, 2025 | quiverquant.comQVivos Therapeutics Secures $1.1M Convertible NoteMay 23, 2025 | tipranks.comEarnings call transcript: Vivos Therapeutics reports Q1 2025 earnings, stock risesMay 17, 2025 | uk.investing.comVivos Therapeutics, Inc: Vivos Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational UpdateMay 17, 2025 | finanznachrichten.deVivos Therapeutics Inc (VVOS) Q1 2025 Earnings Call Highlights: Strategic Acquisitions and FDA ...May 17, 2025 | finance.yahoo.comVivos Therapeutics’ Earnings Call: Strategic Shifts Amid Financial ChallengesMay 16, 2025 | tipranks.comVivos Therapeutics, Inc. (VVOS) Q1 2025 Earnings Call TranscriptMay 15, 2025 | seekingalpha.comVivos Therapeutics, Inc. (VVOS) Reports Q1 Loss, Lags Revenue EstimatesMay 15, 2025 | zacks.comVivos Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational UpdateMay 15, 2025 | finance.yahoo.comVivos Therapeutics Schedules Release of First Quarter 2025 Financial Results and Conference CallMay 15, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLYRA, DXR, TMDIF, and VVOS Company DescriptionsDaxor NASDAQ:DXR$9.00 -0.35 (-3.74%) As of 07/18/2025 11:18 AM EasternDaxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.Lyra Therapeutics NASDAQ:LYRA$7.90 -0.65 (-7.60%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$8.50 +0.60 (+7.59%) As of 07/18/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.Titan Medical NASDAQ:TMDIF$0.38 +0.01 (+2.78%) As of 07/18/2025Titan Medical Inc. operates as a medical technology company. It focuses on the development and licensing of robotic assisted surgical technologies. The company is headquartered in Toronto, Canada.Vivos Therapeutics NASDAQ:VVOS$5.82 +0.09 (+1.57%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$5.80 -0.02 (-0.26%) As of 07/18/2025 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
